Business Context and Reporting Period
This Form 8-K filing by Ironwood Pharmaceuticals, Inc. (IRWD) reports the final voting results from the Company's 2025 Annual Meeting of Stockholders held on June 10, 2025. The filing covers the election of directors, the advisory vote on executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
Director Elections
Stockholders elected nine director nominees to serve one-year terms. All nominees received significant majority support, with "For" votes ranging from approximately 108.4 million to 111.1 million. Broker non-votes totaled 17,527,704 for each nominee.
- Mark Currie, Ph.D.: 110,739,267 For
- Alexander Denner, Ph.D.: 108,426,760 For
- Andrew Dreyfus: 110,282,918 For
- Jon Duane: 109,604,574 For
- Marla Kessler: 110,720,078 For
- Thomas McCourt: 110,995,716 For
- Julie McHugh: 109,518,572 For
- Catherine Moukheibir: 110,936,589 For
- Jay Shepard: 111,094,136 For
Executive Compensation (Say-on-Pay)
The stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- For: 110,089,576
- Against: 3,511,070
- Abstain: 64,325
Auditor Ratification
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for 2025.
- For: 128,241,210
- Against: 2,621,956
- Abstain: 329,509
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes cast "For" each director to assess shareholder sentiment.
- Review the proxy statement referenced in the filing for detailed executive compensation data.
- Confirm the tenure of the newly elected directors and any changes to board committee assignments.
- Check subsequent filings for the Company's Q2 2025 financial results, as this 8-K contains no financial data.